Trio of innovations
The MosaiQ System is powered by a trio of innovations developed by the experts at Quotient.
Microscopic Printing
This novel idea was inspired by microarray technology and combines biochemistry principles with microchip design from the semiconductor industry. The innovative design saves biological and testing resources, as each microarray can be printed with up to 132 biologic spots enabling multiplex results.
Multimodal
The instrument is designed to hold up to four different types of MosaiQ Magazines at once, which would allow for one sample to be tested across different modalities. Well-characterized blood typing and serological and molecular disease screening will be possible with a single tube of blood.
Photometric Immunoassay
This unique reaction uses the direct method for antigen detection and the indirect method for antibody detection. A precise wavelength of light illuminates the spots on the microarray and the high-resolution camera detects results via dark field imaging. An automated algorithm then displays easily readable results on the graphical user interface.
Recent Scientific Publications
These presentations are for education purposes only. Copies of posters and publications are for personal use only and may not be reproduced without permission from the author. Contact communications@quotientbd.com for more information.
Evaluation of the Quotient® MosaiQTM COVID-19 Antibody Microarray for the detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans
The MosaiQ® COVID-19 Antibody test fulfills the minimal requirements for serological testing according to the French regulation.
Evaluation of the MosaiQTM Serological Disease Screening Microarray System for Detection of Antibodies to Human Cytomegalovirus and Treponema pallidum
The study demonstrated that the MosaiQ platform is suitable for screening of blood donations for antibodies to CMV and T. pall. The platform demonstrated suitable sensitivity and specificity to be considered fit for its intended purpose, and has subsequently been submitted for consideration by regulatory bodies.
Evaluation of the performance of the quotient MosaiQTM COVID-19 professional use microarray assay for the detection of antibodies to SARS CoV-2 in a clinical setting
Antibody testing can provide valuable information to guide health- care providers and inform the management of patients. In an ELISA based method, SARS-CoV-2-specific antibodies were detectable in approximately 40% of COVID-19 patients at seven days after the onset of symptoms, and seroconversion rates exceed >90% at the comparatively early time of day 14.
